Verona Pharma PLC Form 4 insider transactions

Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares between October 18 and October 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Verona Pharma's CFO, Mark Hahn, executed multiple sales of ordinary shares through a pre-arranged Rule 10b5-1 trading plan.

Verona Pharma's CEO, David Zaccardelli, executed a sale of 600,000 ordinary shares at an average price of $3.7572 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Verona Pharma's CFO, Mark Hahn, executed a sale of 600,000 ordinary shares on September 11, 2024, at an average price of $3.7568 per share.

Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares through American Depositary Shares (ADSs) under a pre-arranged Rule 10b5-1 trading plan.

Verona Pharma's CFO, Mark Hahn, executed sales of ordinary shares through a pre-arranged 10b5-1 trading plan.

Director David Ebsworth purchased 36,000 ordinary shares of Verona Pharma plc at a price of $2.87 per share on August 12, 2024.

David Zaccardelli, CEO of Verona Pharma, reports acquiring 800,000 ordinary shares upon vesting of performance restricted share units and disposing of 314,800 shares to cover tax obligations.

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma, reports the acquisition and disposal of ordinary shares following the company's first commercial sale of ensifentrine.

Chief Financial Officer Mark Hahn reports acquiring shares through vesting of performance restricted share units and disposing of shares to cover tax obligations.

Mark Hahn, CFO of Verona Pharma plc, reports a transaction involving ordinary shares to cover tax obligations related to vesting restricted share units.

David Zaccardelli, CEO of Verona Pharma plc, reports a transaction involving the withholding of ordinary shares to cover tax obligations related to vested restricted share units.

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc, reports the withholding of ordinary shares to cover tax obligations related to vesting restricted share units.

Mark Hahn, CFO of Verona Pharma plc, reports changes in beneficial ownership due to tax withholding obligations related to vesting Restricted Share Units.

Kathleen Rickard, Chief Medical Officer of Verona Pharma, sold shares to cover tax obligations related to vesting restricted share units and also sold shares under a pre-arranged 10b5-1 trading plan.

Verona Pharma's CEO, David Zaccardelli, disposed of shares to cover tax obligations related to vesting restricted share units.

Director Vikas Sinha acquired 240,000 share options in Verona Pharma plc on April 29, 2024.

Director Martin Edwards of Verona Pharma plc acquired 240,000 share options on April 29, 2024, according to a Form 4 filing with the SEC.

Director Anders Ullman acquired 240,000 share options in Verona Pharma plc on April 29, 2024, according to a recent SEC filing.

Director David Ebsworth acquired 240,000 share options in Verona Pharma plc on April 29, 2024.

Christina Ackermann, a director of Verona Pharma plc, acquired share options exercisable for 240,000 ordinary shares on April 29, 2024.

Director Mahendra Shah reports acquisition of 240,000 share options in Verona Pharma plc.

Director Kenneth Cunningham acquired 240,000 share options in Verona Pharma plc on April 29, 2024.

James Aloysius Brady, a director of Verona Pharma plc, acquired 240,000 share options on April 29, 2024, at an exercise price of $1.9338.

Director Lisa Deschamps acquired 240,000 share options in Verona Pharma plc on April 29, 2024.

Andrew Fisher, General Counsel of Verona Pharma plc, was granted stock options for 2,400,000 ordinary shares on April 1, 2024.